Executive Summary
Core view: Reported Q1 growth was acquisition-led: consolidated revenue rose 88.1%, while standalone organic growth was 16.7%. The ₹1,704 crore order book and Unit-3 expansion support growth, but margin dilution, negative cash flow, debt and promoter pledge keep execution risk high.
Apollo develops electronic and electromechanical subsystems for missiles, naval warfare, avionics, space and homeland security. Ideal Explosives extends the group into explosives, munitions and warheads, creating strategic breadth but breaking year-on-year comparability.
Q1 FY27 Snapshot
Revenue₹251.29 Cr+88.1% consolidated
EBITDA₹53.73 Cr+31.3% YoY
EBITDA margin21.4%vs 30.6% YoY
PAT₹25.22 Cr+42.6% YoY
The consolidated comparison includes Ideal Explosives. Standalone revenue grew 16.7%, which is the cleaner measure of legacy organic growth.
Business Position
Strengths
- Qualified presence in missile, naval, avionics and space programmes.
- Ideal adds explosives and warhead capabilities.
- Consolidated order book of ₹1,704 crore on 8 August 2026.
- Unit-3 can materially expand addressable production.
Constraints
- Q1 growth is not like-for-like after acquisition.
- FY26 CFO was negative ₹130 crore.
- Borrowings reached ₹543 crore.
- About 30.5% of promoter holding was pledged.
Growth Drivers And Capacity Economics
| Driver | Evidence | Investment test |
|---|---|---|
| Unit-3 | ₹300 crore investment targeting roughly 12x capacity | Production before March 2027 must lift utilization without worsening cash conversion. |
| Ideal Explosives | ₹480 crore of consolidated backlog | Integration should recover group margins and create cross-selling. |
| Strategic programmes | Missile, naval, avionics and space applications | Qualified programmes must convert from development into repeat production. |
| Exports | Q1 export revenue was nil | First export wins would diversify a fully domestic quarterly base. |
Standalone backlog was ₹1,224 crore and Ideal added ₹480 crore. The capacity case is attractive only if procurement, working capital and commissioning move together.
Management Guardrails And Credibility
| Operating objective | Status | Evidence required |
|---|---|---|
| FY27 revenue growth of 40-45% | Reported pace ahead | Organic and acquisition contributions must be separated through FY27. |
| Complete Unit-3 before March 2027 | In progress | Commissioning, approvals and utilization milestones should remain on schedule. |
| Integrate explosives and electronics | Early stage | Order conversion and consolidated margin recovery are key. |
| Improve financial quality | Watch | Operating cash flow must turn positive despite growth and capex. |
No formal EBITDA-margin guidance was disclosed. Our scenario therefore assumes gradual recovery rather than extrapolating either Q1's 21.4% or the prior-year 30.6% margin.
Financial Quality
FY26 revenue₹904 Cr+61% YoY
FY26 PAT₹107 CrNearly doubled
FY26 borrowings₹543 CrElevated funding load
FY26 CFO-₹130 CrBelow reported profit
| Quality test | Reading | Interpretation |
|---|---|---|
| ROCE | 14.5% | Moderate before a large new capacity programme. |
| Cash conversion | Negative ₹130 crore CFO | Working capital absorbed more cash than accounting profit generated. |
| Leverage | ₹543 crore borrowings | Raises sensitivity to commissioning and collection delays. |
| Ownership | 49.98% promoter; about 30.5% pledged | Pledge and recent issuance deserve close monitoring. |
Valuation
At ₹422.25 on 11 September 2026, market capitalization was approximately ₹15,691 crore and trailing P/E about 129.3x. The price already discounts rapid order conversion, acquisition integration and a successful Unit-3 ramp.
| Scenario | FY28 revenue | PAT margin | Illustrative PAT | Current market-cap / PAT |
|---|---|---|---|---|
| Bear | ₹1,550 Cr | 8% | ₹124 Cr | 127x |
| Base | ₹1,750 Cr | 10% | ₹175 Cr | 90x |
| Bull | ₹1,950 Cr | 12% | ₹234 Cr | 67x |
Even the bull case remains expensive. Revenue without operating cash flow or with sustained margin dilution would not support the current valuation.
Key Risks
- Acquisition-led figures obscure organic performance.
- Unit-3 commissioning or customer approvals slip.
- Negative CFO and working-capital needs force more financing.
- Debt and promoter pledge increase financial risk.
- Domestic procurement remains lumpy; Q1 exports were nil.
Annual Projection
| Period | Revenue | EBITDA margin | PAT | Key condition |
|---|---|---|---|---|
| FY27E | ₹1,266-1,311 Cr | 22-24% | ₹138-153 Cr | Management's 40-45% growth guidance is achieved. |
| FY28E | ₹1,550-1,850 Cr | 23-26% | ₹155-215 Cr | Unit-3 and Ideal scale with better cash conversion. |
| FY29E | ₹1,850-2,250 Cr | 24-27% | ₹205-285 Cr | Exports and integrated munitions programmes broaden. |
These are analytical scenarios, not management guidance beyond FY27. EPS uses approximately 37.16 crore shares and may change with future issuance.
Investor Watchlist
- Standalone organic growth versus consolidated acquisition growth.
- Ideal margin, order execution and integration.
- Unit-3 commissioning and utilization.
- Operating cash flow, borrowings and promoter pledge.
- First material export revenue.
Sources Used
Prepared on 13 September 2026 from public information. Forecasts are analytical estimates and not investment advice.